Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.